IP clash with Novartis reflects India's tensions with international pharma

Novartis CEO Joseph Jimenez wrote a letter to Indian Commerce and Industry Minister Anand Sharma saying that the official had misrepresented company's view on Indian patent laws. "During a recent visit to Washington, D.C., I learned of statements attributed to you by a member of the United States Senate and the head of PhRMA that Novartis is 'pleased' with India's [intellectual-property] laws. Let me assure you this is not the case," Jimenez's letter reads. An aide to Sharma defended the nation's patent policies and responded that the minister had been referring to another drugmaker. The incident reflects the level of acrimony between India and international drugmakers over patents, according to this article.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief: